ArticleFrontiers in oncology2026
Dynamic volume perfusion CT for preoperative multidimensional resectability assessment of pancreatic ductal adenocarcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to evaluate the performance of dynamic volume perfusion computed tomography (dVPCT) in the preoperative multidimensional assessment of resectability in patients with pancreatic ductal adenocarcinoma (PDAC). Methods: We retrospectively collected clinical data from 53 patients with pathologically confirmed PDAC who underwent preoperative epigastric dVPCT. By performing morphological reconstruction, we assessed the degree of involvement of major peripancreatic vessels and compared the predicted resectability status of PDAC lesions against the records from surgical explorations. CT perfusion parameters, including blood flow (BF), blood volume (BV), surface permeability (PS), and mean transit time (MTT), were measured for each patient diagnosed with PDAC. Patients were categorized into resectable and unresectable groups on the basis of the operative findings, and differences in perfusion parameters between these groups were compared via the Mann-Whitney U test. Receiver operating characteristic (ROC) curve analysis was conducted to establish threshold values and areas under the curve (AUCs) for each perfusion parameter as predictors of PDAC resectability. Results: The sensitivity, specificity, positive prediction value, negative prediction value and accuracy of dVPCT for the diagnosis of peripancreatic arterial invasion were 88.2%, 100%, 100%, 97.8%, and 98.1%, respectively, whereas those for venous invasion were 88.9%, 98.9%, 94.1%, 97.8%, and 97.2%, respectively. For assessing the resectability of PDAC, dVPCT demonstrated a sensitivity of 88.5%, a specificity of 92.6%, a positive predictive value of 92.0%, a negative predictive value of 89.3%, and an accuracy of 90.6%. BF and BV values were significantly lower in the unresectable PDAC group than in the resectable group. The cutoff value for BF for diagnosing resectable PDAC was determined to be 49.9 mL/100 mL/min, with an AUC of 0.732 (95% confidence interval [CI]: 0.593-0.871).Similarly, the cutoff value for BV for the diagnosis of resectable PDAC was 4.3 mL/100 mL, yielding an AUC of 0.714 (95% CI: 0.575-0.853). Conclusion: Our preliminary study demonstrated that dVPCT permits the simultaneous acquisition of both high-quality morphological images and stable perfusion parameters for PDAC evaluation. These findings suggest that in cases of morphologically uncertain resectability, the derived perfusion parameters may provide complementary information and could serve as adjunctive tools to conventional imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.